Overview

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients with Grade I or II essential hypertension.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Amlodipine
Azilsartan medoxomil
Hydrochlorothiazide